Valneva SE Shareholding Declaration - March 2025 VALNEVA Declaration of shares and voting rights March 31, 2025__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: April 3, 2025 Number of shares composing the share capital of Valneva Total number of voting rights including suspended voting rights* Description of the change Date on which this change was recognized Total numb...
Déclaration d'actions et de droits de vote de la société Valneva SE - Mars 2025 VALNEVA Déclaration d’actions et de droits de vote 31 mars 2025__________________________________________________________________________________________ Dénomination sociale : VALNEVAAdresse du siège social : 6 rue Alain Bombard, 44800 Saint-HerblainMarché réglementé Euronext Paris - Compartiment B Date de la déclaration : 3 avril 2025 Nombre d’actions composant le capital de Valneva Nombre total de droits de vote incluant les droits de vote suspendus* Origine de la variation Date à laquelle ce...
Valneva announced that the EC has granted marketing authorization in EU for Ixchiq in individuals aged >12y.o, marking an important step in line with the label extension strategy for the asset as well as allowing Valneva to close the gap on the label presented by Bavarian's Vimkunya (approved in
Valneva’s Chikungunya Vaccine IXCHIQ® Now Authorized in EU for Adolescents Aged 12 and Above With this extension, IXCHIQ®, the first vaccine against the chikungunya virus (CHIKV), is now available for administration for individuals 12 years of age and older in the European Union (EU). Saint Herblain (France), April 1, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ®, for the prevention of disease caused by the chikungunya virus ...
Valneva : le vaccin contre le chikungunya, IXCHIQ®, désormais autorisé chez les adolescents dans l'UE Avec cet élargissement d’indication, IXCHIQ®, le premier vaccin autorisé au monde contre le virus du chikungunya (CHIKV), est désormais disponible pour une administration dans l'Union Européenne (UE) chez les personnes âgées de 12 ans et plus. Saint Herblain (France), le 1er avril 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui que la Commission Européenne (CE) a accordé une autorisation de mise sur le marché à IXCHIQ®, le vaccin à...
Transactions in connection with share buyback programme Company Announcement Copenhagen, 31 March 2025 No. 23/2025 Transactions in connection with share buyback programmeISS A/S, a leading workplace experience and facility management company, announced on 20 February 2025 a new share buyback programme, see company announcement no. 12/2025. The share buyback programme is executed in accordance Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 (the “Market Abuse Regulation”) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also...
EQS-News: NORMA Group SE / Schlagwort(e): Jahresergebnis/Jahresbericht NORMA Group mit solidem Ergebnis 2024 und verhaltenem Ausblick auf Entwicklung im aktuellen Geschäftsjahr 31.03.2025 / 07:05 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. NORMA Group mit solidem Ergebnis 2024 und verhaltenem Ausblick auf Entwicklung im aktuellen Geschäftsjahr Konzernumsatz geht 2024 um 5,5 Prozent auf 1.155,1 Millionen Euro zurück Bereinigtes EBIT bei 92,3 Millionen Euro; bereinigte EBIT-Marge bei 8,0 Prozent Starker Cashflow von 105,4 Million...
EQS-News: NORMA Group SE / Key word(s): Annual Results/Annual Report NORMA Group with sound earnings in 2024 and cautious outlook for development in the current financial year 31.03.2025 / 07:05 CET/CEST The issuer is solely responsible for the content of this announcement. NORMA Group with sound earnings in 2024 and cautious outlook for development in the current financial year Group sales 2024 down 5.5 percent to EUR 1,155.1 million Adjusted EBIT at EUR 92.3 million; adjusted EBIT margin at 8.0 percent Strong cash flow of EUR 105.4 million Dividend of EUR 0.40 per s...
Valneva Submits Adolescent Label Extension Application for its Chikungunya Vaccine, IXCHIQ®, to UK MHRA Saint Herblain (France), March 31, 2025 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted a label extension application to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom (UK) to potentially expand the use of its chikungunya vaccine, IXCHIQ®, currently approved in adults1, to adolescents aged 12 to 17 years in the UK. This submission follows the recent positive opinion of the European Medicines A...
Valneva soumet à la MHRA une demande d’élargissement de l’indication aux adolescents pour son vaccin contre le chikungunya IXCHIQ® Saint Herblain (France), le 31 mars 2025 – (Nasdaq: VALN; Euronext Paris: VLA), société spécialisée dans les vaccins, a annoncé aujourd’hui avoir soumis une demande d’élargissement de l’indication de son vaccin contre le chikungunya IXCHIQ® à l’agence de santé britannique, Medicines and Healthcare products Regulatory Agency (MHRA), visant à potentiellement élargir au Royaume-Uni l’utilisation de son vaccin, actuellement approuvé chez les adultes1, aux adolescen...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.